BLTE – Belite Bio Inc ADR
BLTE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.12
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.33
EPS Last/This Y
0.18
EPS This/Next Y
2.92
Price
137.14
Target Price
211.5
Analyst Recom
1
Performance Q
-27.45
Upside
-164.5%
Beta
-1.22
Ticker: BLTE
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | BLTE | 164.1 | N/A | N/A | 0 |
| 2026-04-24 | BLTE | 161.27 | N/A | N/A | 0 |
| 2026-04-27 | BLTE | 164.03 | N/A | N/A | 0 |
| 2026-04-28 | BLTE | 159.33 | N/A | N/A | 0 |
| 2026-04-29 | BLTE | 154.71 | N/A | N/A | 0 |
| 2026-04-30 | BLTE | 159.61 | N/A | N/A | 0 |
| 2026-05-01 | BLTE | 155.53 | N/A | N/A | 0 |
| 2026-05-04 | BLTE | 154.93 | N/A | N/A | 0 |
| 2026-05-05 | BLTE | 154.15 | N/A | N/A | 0 |
| 2026-05-06 | BLTE | 156.27 | N/A | N/A | 0 |
| 2026-05-07 | BLTE | 156.34 | N/A | N/A | 0 |
| 2026-05-08 | BLTE | 155.74 | N/A | N/A | 0 |
| 2026-05-11 | BLTE | 152.25 | N/A | N/A | 0 |
| 2026-05-12 | BLTE | 156.54 | N/A | N/A | 0 |
| 2026-05-13 | BLTE | 153.81 | N/A | N/A | 0 |
| 2026-05-14 | BLTE | 149.98 | N/A | N/A | 0 |
| 2026-05-15 | BLTE | 142.49 | N/A | N/A | 0 |
| 2026-05-18 | BLTE | 142.32 | N/A | N/A | 0 |
| 2026-05-19 | BLTE | 139.24 | N/A | N/A | 0 |
| 2026-05-20 | BLTE | 143.51 | N/A | N/A | 0 |
| 2026-05-21 | BLTE | 143.92 | N/A | N/A | 0 |
| 2026-05-22 | BLTE | 137.3 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | BLTE | 164.27 | -42.9 | - | -2.13 |
| 2026-04-24 | BLTE | 161.20 | -42.9 | - | -2.13 |
| 2026-04-27 | BLTE | 163.62 | -42.9 | - | -2.13 |
| 2026-04-28 | BLTE | 159.05 | -42.9 | - | -2.13 |
| 2026-04-29 | BLTE | 154.66 | -42.9 | - | -2.13 |
| 2026-04-30 | BLTE | 159.24 | -42.9 | - | -2.13 |
| 2026-05-01 | BLTE | 154.85 | -42.9 | - | -2.13 |
| 2026-05-04 | BLTE | 154.76 | -42.9 | - | -2.13 |
| 2026-05-05 | BLTE | 154.16 | -42.9 | - | -2.13 |
| 2026-05-06 | BLTE | 156.35 | -42.9 | - | -2.13 |
| 2026-05-07 | BLTE | 156.00 | -42.9 | - | -2.13 |
| 2026-05-08 | BLTE | 155.35 | -42.9 | - | -2.13 |
| 2026-05-11 | BLTE | 152.50 | -42.9 | - | -2.13 |
| 2026-05-12 | BLTE | 156.16 | -42.9 | - | -2.13 |
| 2026-05-13 | BLTE | 153.89 | -42.9 | - | -2.13 |
| 2026-05-14 | BLTE | 150.27 | -42.9 | - | -2.13 |
| 2026-05-15 | BLTE | 142.38 | -42.9 | - | -2.13 |
| 2026-05-18 | BLTE | 142.82 | -42.9 | - | -2.13 |
| 2026-05-19 | BLTE | 139.52 | -42.9 | - | -2.13 |
| 2026-05-20 | BLTE | 143.68 | -42.9 | - | -2.13 |
| 2026-05-21 | BLTE | 143.92 | -42.9 | - | -2.13 |
| 2026-05-22 | BLTE | 137.14 | -42.9 | - | -2.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | BLTE | -5.89 | 5.78 | 2.64 |
| 2026-04-24 | BLTE | -6.40 | 5.78 | 2.64 |
| 2026-04-27 | BLTE | -6.65 | 5.73 | 2.81 |
| 2026-04-28 | BLTE | -6.91 | 5.73 | 2.81 |
| 2026-04-29 | BLTE | -7.16 | 5.73 | 2.81 |
| 2026-04-30 | BLTE | -7.41 | 5.73 | 2.81 |
| 2026-05-01 | BLTE | -7.66 | 5.73 | 2.81 |
| 2026-05-04 | BLTE | -7.90 | 5.58 | 2.81 |
| 2026-05-05 | BLTE | -7.90 | 5.58 | 2.81 |
| 2026-05-06 | BLTE | -8.15 | 5.58 | 2.81 |
| 2026-05-07 | BLTE | -8.39 | 5.58 | 2.81 |
| 2026-05-08 | BLTE | -8.64 | 5.58 | 2.81 |
| 2026-05-11 | BLTE | -8.80 | 5.02 | 2.81 |
| 2026-05-12 | BLTE | -8.80 | 5.02 | 3.11 |
| 2026-05-13 | BLTE | -8.80 | 5.02 | 3.11 |
| 2026-05-14 | BLTE | -8.80 | 5.02 | 3.11 |
| 2026-05-15 | BLTE | -9.40 | 5.02 | 3.11 |
| 2026-05-18 | BLTE | -9.40 | 5.13 | 3.11 |
| 2026-05-19 | BLTE | -9.40 | 5.13 | 3.11 |
| 2026-05-20 | BLTE | -9.40 | 5.13 | 3.11 |
| 2026-05-21 | BLTE | -9.40 | 5.13 | 3.11 |
| 2026-05-22 | BLTE | -9.40 | 5.13 | 3.12 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
22 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.34
Avg. EPS Est. Current Quarter
-0.64
Avg. EPS Est. Next Quarter
-0.67
Insider Transactions
-9.4
Institutional Transactions
5.13
Beta
-1.22
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
14
Growth Score
23
Sentiment Score
55
Actual DrawDown %
31.4
Max Drawdown 5-Year %
Target Price
211.5
P/E
Forward P/E
119.65
PEG
P/S
P/B
6.92
P/Free Cash Flow
EPS
-2.53
Average EPS Est. Cur. Y
-2.13
EPS Next Y. (Est.)
0.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.68
Return on Equity vs Sector %
-38.4
Return on Equity vs Industry %
-22.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
◆
BLTE
Healthcare
$137.30
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
16/20
Pullback
13/25
Volume
9/15
Valuation
13/20
TP/AR
2/10
Options
0/10
RSI
31.3
Range 1M
4.8%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
13/25
Growth
13/30
Estimates
0/20
Inst/Vol
6/15
Options
0/10
EPS Yr
-38.8%
EPS NY
135.8%
52W%
56.5%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-41.6% upside
Quality
3/30
Valuation
0/30
Growth
9/25
Stability
7/10
LT Trend
1/5
Upside
-41.6%
Quality
14
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 41
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE
Latest News
—
Caricamento notizie per BLTE…
stock quote shares BLTE – Belite Bio Inc ADR Stock Price stock today
news today BLTE – Belite Bio Inc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch BLTE – Belite Bio Inc ADR yahoo finance google finance
stock history BLTE – Belite Bio Inc ADR invest stock market
stock prices BLTE premarket after hours
ticker BLTE fair value insiders trading